{
  "resourceType": "ClinicalUseDefinition",
  "id": "atezolizumab-signet-ring-cell-variant-cervical-mucinous-adenocar",
  "meta": {
    "profile": [
      "http://hl7.org/fhir/StructureDefinition/ClinicalUseDefinition"
    ]
  },
  "type": "indication",
  "status": {
    "coding": [
      {
        "system": "http://hl7.org/fhir/publication-status",
        "code": "draft",
        "display": "Draft"
      }
    ]
  },
  "subject": [
    {
      "reference": "MedicationKnowledge/atezolizumab"
    }
  ],
  "indication": {
    "diseaseSymptomProcedure": {
      "concept": {
        "text": "signet ring cell variant cervical mucinous adenocarcinoma"
      }
    }
  },
  "extension": [
    {
      "url": "https://twtxgnn.yao.care/fhir/StructureDefinition/prediction-status",
      "valueCode": "predicted"
    },
    {
      "url": "https://twtxgnn.yao.care/fhir/StructureDefinition/evidence-level",
      "valueCode": "L5"
    },
    {
      "url": "https://twtxgnn.yao.care/fhir/StructureDefinition/txgnn-score",
      "valueDecimal": 0.9991
    }
  ]
}